Angeliq - Comprehensive Research Paper

Document Version: 1.0 Last Updated: 2025-12-26 Classification: HRT Research - Combination Estrogen/Progestin Products (Oral) Paper Number: 43 of 76

1. Summary

1.1 Executive Summary

Angeliq is an oral combination hormone replacement therapy (HRT) containing estradiol and drospirenone (DRSP) for postmenopausal women with an intact uterus. It is unique among oral combination HRT products due to drospirenone's anti-mineralocorticoid and anti-androgenic properties, which derive from its spironolactone-like structure. These properties may provide benefits for patients with fluid retention, mild hypertension, or androgen-related symptoms, but require monitoring for hyperkalemia in at-risk patients.

Key Distinguishing Features:

• Anti-mineralocorticoid activity: Drospirenone counteracts estrogen-induced sodium/water retention
• Anti-androgenic activity: May benefit acne, hirsutism, seborrhea
• Potential blood pressure reduction: Unlike other HRT products, may lower BP
• Hyperkalemia risk: Requires potassium monitoring in high-risk patients
• No generic available: Brand-only product; higher cost

FDA-Approved Indications (in women with intact uterus):

| Indication | 0.25 mg/0.5 mg | 0.5 mg/1 mg | |---

Goal Relevance:

• Manage hot flashes and night sweats during menopause
• Improve vaginal health and reduce dryness for postmenopausal women
• Address fluid retention and bloating associated with hormone therapy
• Support mild blood pressure reduction in women experiencing hypertension during menopause
• Help with acne and oily skin related to hormonal changes
• Provide an option for women who have experienced positive results with drospirenone-containing birth control pills

---------|----------------|-------------| | Moderate to severe vasomotor symptoms | Yes | Yes | | Vulvar and vaginal atrophy | No | Yes | | Prevention of postmenopausal osteoporosis | Not indicated | Not indicated |

Safety Profile:

• Common (>10%): Breast pain/discomfort (17.9%), vaginal bleeding (14%)
• Serious risks: Hyperkalemia (unique to DRSP), VTE, stroke, MI, breast cancer
• Potassium monitoring: Required in patients on ACE-I, ARBs, K-sparing diuretics

Current Formulations:

Manufacturer: Bayer HealthCare Pharmaceuticals

1.2 Chemical and Pharmacological Classification

Estradiol Component:

• Chemical Name: 17β-Estradiol
• Molecular Formula: C₁₈H₂₄O₂
• Molecular Weight: 272.39 g/mol
• CAS Number: 50-28-2
• Class: Bioidentical estrogen

Drospirenone Component:

• Chemical Name: 6β,7β,15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone
• Molecular Formula: C₂₄H₃₀O₃
• Molecular Weight: 366.49 g/mol
• CAS Number: 67392-87-4
• Class: Synthetic progestin (spironolactone derivative, 4th generation)
• Parent Compound: Derived from 17α-spirolactone

Unique Progestin Classification:

Unlike other progestins derived from testosterone (19-nortestosterone derivatives) or progesterone, drospirenone is structurally related to spironolactone, giving it unique pharmacological properties:

Product Classification:

• Drug Class: Combination estrogen/progestin HRT with anti-mineralocorticoid activity
• Delivery System: Oral tablet (film-coated)
• Regimen Type: Continuous combined
• Application Frequency: Once daily

1.3 Historical Background

Development Timeline:

• 1987: Drospirenone first described in literature
• 2001: Yasmin (DRSP + ethinyl estradiol) approved as first drospirenone product (contraceptive)
• 2005 (Sept 28): Angeliq 0.5 mg/1 mg approved by FDA for HRT
• 2012 (Feb 29): Angeliq 0.25 mg/0.5 mg approved (lower dose)
• Present: Remains brand-only; no generic available in U.S.

Manufacturer: Bayer HealthCare Pharmaceuticals (originally Berlex/Schering)

Development Rationale:

Drospirenone was developed to create a progestin with a pharmacological profile closer to natural progesterone, particularly its anti-mineralocorticoid effects. Spironolactone served as the structural template, providing the anti-aldosterone and anti-androgenic properties not seen in testosterone-derived progestins.

Related Drospirenone Products:

1.4 Key Clinical Differentiators

Versus Other Oral Combination HRT:

When to Consider Angeliq:

• Patients with fluid retention/bloating on other HRT
• Mild hypertension (anti-mineralocorticoid effect)
• Androgen-related symptoms (acne, hirsutism, oily skin)
• Patients who tolerated drospirenone-containing OCPs well

When to Avoid Angeliq:

• Renal impairment (hyperkalemia risk)
• Hepatic impairment (hyperkalemia risk)
• Adrenal insufficiency (hyperkalemia risk)
• Concurrent potassium-elevating drugs without monitoring
• Cost-sensitive patients (no generic available)

2. Mechanism of Action

2.1 Estradiol Component

Estrogen Receptor Binding:

Genomic Mechanism:

1. Estradiol enters target cells
2. Binds to cytoplasmic/nuclear estrogen receptors (ERα, ERβ)
3. Receptor-hormone complex translocates to nucleus
4. Binds estrogen response elements (EREs) on DNA
5. Modulates transcription of target genes
6. Effects manifest over hours to days

Key Estrogen Target Tissues:

2.2 Drospirenone Component

Triple Receptor Activity:

Drospirenone is pharmacologically unique among progestins, exhibiting activity at three receptor types:

Progestogenic Activity:

Anti-Mineralocorticoid Activity:

This is drospirenone's most distinctive property, derived from its spironolactone-related structure:

Comparison to Spironolactone:

Anti-Androgenic Activity:

2.3 Combined E2/DRSP Effects

Synergistic Benefits:

Continuous Combined Regimen:

Daily administration of both E2 and DRSP leads to:

• Consistent hormone levels (no cycling)
• Endometrial atrophy (reduced bleeding)
• High amenorrhea rates by month 12

2.4 Receptor Binding Profile Comparison

Drospirenone vs. Other Progestins:

Clinical Implications:

• DRSP: Reduces bloating, may lower BP, may help acne
• NETA: Neutral on fluid, mild androgenic
• LNG: Androgenic (may worsen acne/hirsutism)
• MPA: May cause fluid retention (mild MC agonist)

3. FDA-Approved Indications

3.1 Approved Indications

For Women with an Intact Uterus:

Vasomotor Symptoms (Both Strengths):

• Moderate to severe hot flashes due to menopause
• Requires intact uterus (progestin for endometrial protection)
• Start with lower dose; titrate based on response

Vulvar and Vaginal Atrophy (Higher Strength Only):

• Moderate to severe symptoms due to menopause
• Consider topical therapy first per FDA guidance
• Use lowest effective dose for shortest duration

3.2 Important Limitations

NOT Approved For:

WHI-Based Limitations:

3.3 Patient Selection

Ideal Candidate:

NOT Ideal Candidate:

4. Dosing and Administration

4.1 Available Formulations

Angeliq Tablets:

Packaging:

• 28 tablets per pack (1 month supply)
• Blister pack
• Continuous regimen (no placebo tablets)

4.2 Dosing Recommendations

General Dosing:

Administration:

Continuous Regimen:

• No treatment-free interval
• Each 28-day pack followed immediately by next pack
• Designed to achieve endometrial atrophy

4.3 Initiation Considerations

Timing of Initiation:

Pre-Treatment Assessment:

4.4 Special Dosing Situations

Renal Impairment:

Hepatic Impairment:

Concurrent K+-Elevating Drugs:

4.5 Duration of Therapy

General Principles:

Tapering:

There is no established tapering protocol. Options include:

• Gradual dose reduction (if using higher strength)
• Alternate day dosing
• Abrupt discontinuation with monitoring

5. Pharmacokinetics

5.1 Estradiol Pharmacokinetics

Absorption:

Distribution:

Metabolism:

Excretion:

5.2 Drospirenone Pharmacokinetics

Absorption:

Distribution:

Metabolism:

Key Metabolic Point:

Unlike most progestins, drospirenone metabolism is largely independent of the CYP450 system. The two major metabolites (drospirenone acid and 4,5-dihydrodrospirenone 3-sulfate) are formed via non-CYP pathways. However, CYP3A4 does contribute to oxidative metabolism, and strong inhibitors can moderately increase DRSP levels.

Excretion:

5.3 Drug-Drug Interactions (PK-Based)

CYP3A4 Interactions:

Effect of DRSP on Other Drugs:

5.4 Pharmacokinetic Comparison

DRSP vs. Other Progestins:

5.5 Special Population Pharmacokinetics

Age:

No clinically significant differences in DRSP pharmacokinetics in postmenopausal women compared to younger women (from contraceptive studies).

Renal Impairment:

Hepatic Impairment:

6. Side Effects and Adverse Reactions

6.1 Overview

Angeliq shares the class adverse effects of all estrogen plus progestin HRT products, with additional considerations related to drospirenone's unique anti-mineralocorticoid activity. The hyperkalemia risk distinguishes Angeliq from other HRT products.

6.2 Common Adverse Reactions

From Clinical Trials (Angeliq 0.25 mg DRSP/0.5 mg E2):

From Clinical Trials (Angeliq 0.5 mg DRSP/1 mg E2):

6.3 Adverse Reactions by System

Breast:

Genitourinary:

Bleeding Pattern Over Time:

Gastrointestinal:

Neurological:

Other Common:

6.4 Drospirenone-Specific Considerations

Hyperkalemia:

This is the most distinctive safety concern for Angeliq:

Fluid Balance:

6.5 Serious Adverse Reactions

Class Effects (All Estrogen + Progestin):

Unique to Drospirenone:

6.6 Post-Marketing Reports

Immune System:

• Hypersensitivity reactions (rash, pruritus, urticaria)

Reproductive/Breast:

• Breast cancer (class effect)

Vascular:

• Venous thromboembolic events (DVT, PE)
• Arterial thromboembolic events (MI, stroke)

6.7 Discontinuation Due to Adverse Events

Most Common Reasons for Discontinuation:

7. Drug Interactions

7.1 Hyperkalemia-Related Interactions (Most Important)

Potassium-Elevating Drugs:

Clinical Trial Data (Enalapril + DRSP/E2):

Monitoring Protocol:

7.2 CYP3A4 Interactions

CYP3A4 Inhibitors (Increase DRSP Levels):

CYP3A4 Inducers (Decrease DRSP Levels):

Important Note:

Unlike many progestins, DRSP metabolism is only marginally dependent on CYP450. Most metabolism occurs via non-CYP pathways (lactone ring opening, reduction, sulfation). Thus, CYP3A4 interactions are generally moderate rather than dramatic.

7.3 Estradiol Interactions

CYP3A4 Inducers (Decrease E2):

CYP3A4 Inhibitors (Increase E2):

Strong CYP3A4 inhibitors may increase estradiol levels, potentially increasing estrogen-related side effects.

7.4 Effects of Angeliq on Other Drugs

Generally Does NOT Affect:

Drospirenone does not significantly inhibit or induce CYP enzymes at therapeutic doses.

7.5 Other Clinically Relevant Interactions

Thyroid Hormone:

Warfarin:

Antidiabetic Agents:

7.6 Interaction Summary Table

8. Contraindications

8.1 Absolute Contraindications

Unique to Angeliq (Drospirenone-Related):

Class Contraindications (All Estrogen + Progestin):

8.2 Warnings and Precautions

Cardiovascular and VTE:

Malignancy:

Hyperkalemia:

Dementia:

Gallbladder Disease:

Estrogens increase risk of gallbladder disease (cholelithiasis, cholecystitis).

Other:

• Hypertriglyceridemia (oral estrogen may increase TG)
• Fluid retention (though DRSP may reduce)
• Exacerbation of endometriosis, asthma, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas

8.3 Contraindication Comparison

9. Special Populations

9.1 Renal Impairment

Critical Consideration for Angeliq:

Comparison with Other HRT:

Most other HRT products (Activella, Prempro, Climara Pro) do not have specific renal contraindications since their progestins lack anti-mineralocorticoid activity.

9.2 Hepatic Impairment

9.3 Age Considerations

Older Women (≥65 years):

Timing Hypothesis:

9.4 Cardiovascular Risk Factors

9.5 Migraine History

9.6 History of Thromboembolic Disease

9.7 Endometriosis History

9.8 Breast Cancer Risk

Risk Factors:

Duration Effect:

10. Monitoring Parameters

10.1 Baseline Assessment

Before Starting Angeliq:

10.2 Potassium Monitoring (Unique to Angeliq)

Who Needs K+ Monitoring:

Potassium Levels:

10.3 Ongoing Monitoring

Routine Follow-Up:

10.4 Symptom Response Monitoring

Vasomotor Symptoms:

Vaginal Symptoms:

10.5 Bleeding Surveillance

Expected Pattern:

When to Evaluate:

10.6 Breast Cancer Surveillance

Protocol:

Patient Education:

• Report lumps, skin changes, nipple discharge promptly
• Risk increases with duration of E+P use
• Benefits vs. risks reviewed annually

10.7 Reassessment Schedule

Annual Review:

When to Consider Discontinuation:

• Symptoms resolved
• Unacceptable side effects
• New contraindication develops
• Risk profile changes
• Patient preference

11. Cost and Availability

11.1 Pricing Overview

Average Wholesale Price (AWP) - 2024:

Patient Cost Examples (Monthly):

11.2 Insurance Coverage

Typical Tier Placement:

Coverage Challenges:

11.3 Generic Availability

Status: NO GENERIC AVAILABLE (as of 2024)

Comparison with Alternatives:

11.4 Patient Assistance Programs

Bayer Patient Assistance:

General Resources:

11.5 Cost Comparison with Alternatives

Monthly Cost Comparison:

Cost-Effectiveness Considerations:

When Cost Justifies Angeliq:

• Failed or intolerant to generic E+P options
• Specific need for anti-mineralocorticoid effect
• Fluid retention/bloating on other HRT
• Androgen-related symptoms (acne, hirsutism)
• Mild hypertension that could benefit from anti-MC

12. Clinical Evidence Summary

12.1 Pivotal Efficacy Trials

Vasomotor Symptoms Trial (Angeliq 0.25/0.5 mg):

Results:

12.2 Blood Pressure Studies

Angeliq BP Trial in Hypertensive Women:

Results:

Clinical Implication:

Angeliq is the only combination HRT product with demonstrated BP-lowering potential, making it potentially advantageous for hypertensive postmenopausal women.

12.3 Endometrial Safety

One-Year Endometrial Trial:

Results:

12.4 Bleeding Pattern Data

Bleeding Over Time:

Amenorrhea Rates:

12.5 Hyperkalemia Safety Data

Clinical Trial Summary:

Interpretation:

In controlled trials, no patients developed hyperkalemia. However, real-world use with multiple K+-elevating drugs or renal impairment may pose higher risk.

12.6 Long-Term Safety Context

WHI Data Extrapolation:

While WHI studied CEE+MPA (not E2+DRSP), class effects are assumed:

Potential Differences (E2+DRSP vs. CEE+MPA):

12.7 Quality of Life Evidence

Patient-Reported Outcomes:

13. Comparison with Alternatives

13.1 Comparison with Other Oral E+P Products

13.2 Angeliq vs. Activella

When to Choose Angeliq Over Activella:

When to Choose Activella Over Angeliq:

13.3 Angeliq vs. Prempro

13.4 Angeliq vs. Transdermal Options

When to Consider Transdermal Over Angeliq:

When to Consider Angeliq Over Transdermal:

13.5 Decision Framework

Choosing Angeliq:

Choosing Alternative:

14. Storage and Handling

14.1 Storage Requirements

Temperature:

14.2 Packaging and Protection

Protection Requirements:

Packaging:

• Blister pack (28 tablets)
• Continuous regimen (no placebo)
• Child-resistant features

14.3 Dispensing Considerations

Pharmacist Notes:

Special Counseling for Angeliq:

14.4 Stability

Shelf Life:

14.5 Disposal

Patient Instructions:

15. References

15.1 Prescribing Information

1. Angeliq (drospirenone and estradiol) tablets prescribing information. Bayer HealthCare Pharmaceuticals. Most recent revision 2023.

2. FDA Drug Approval Package: Angeliq NDA 021355. U.S. Food and Drug Administration. 2005.

3. Supplemental NDA Approval: Angeliq 0.25 mg/0.5 mg. FDA. 2012.

15.2 Clinical Guidelines

4. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.

5. ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202-216. (Reaffirmed 2018)

6. Endocrine Society Clinical Practice Guideline: Treatment of Symptoms of the Menopause. J Clin Endocrinol Metab. 2015;100(11):3975-4011.

15.3 Drospirenone Pharmacology

7. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62(1):29-38.

8. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80(6):1816-1821.

9. Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric. 2005;8(Suppl 3):4-12.

15.4 Clinical Trial References

10. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005;12(6):716-727.

11. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17β-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation. 2005;112(13):1979-1984.

12. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005;18(6):797-804.

15.5 WHI and Long-Term Safety

13. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.

14. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368.

15.6 Progestin Comparisons

15. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34(2):171-208.

16. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(Suppl 1):3-63.

15.7 Hyperkalemia and Drug Interactions

17. FDA Drug Safety Communication: Safety review update of medications used to block the renin-angiotensin system and hyperkalemia. FDA. 2016.

18. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585-592.

15.8 Cost and Access Resources

19. RED BOOK Online. IBM Micromedex. (AWP pricing data)

20. GoodRx drug pricing. https://www.goodrx.com

21. Bayer Patient Assistance Programs. https://www.bayer.com

15.9 Patient Resources

22. The North American Menopause Society. https://www.menopause.org

23. American College of Obstetricians and Gynecologists Patient Education. https://www.acog.org/patient-resources

24. FDA MedWatch Safety Information. https://www.fda.gov/safety/medwatch

15.10 Additional References

25. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-845.

26. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.

27. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231.

16. Goal Archetype Integration

16.1 E2 + DRSP Combination Rationale

Why This Combination is Unique:

The estradiol-drospirenone combination in Angeliq represents a pharmacologically distinct approach to HRT that addresses multiple therapeutic goals simultaneously:

16.2 Goal Archetype Mapping

Primary Goal Archetypes Best Served by Angeliq:

Goal Archetypes Where Alternatives May Be Better:

16.3 Anti-Mineralocorticoid Benefit Deep Dive

Mechanism-Based Benefits:

Quantified Anti-MC Effect:

Patient Selection Based on Anti-MC Need:

17. Age-Stratified Dosing

17.1 Dosing by Age and Menopausal Status

Age-Based Dosing Framework:

17.2 Age-Related Risk Considerations

Risk Factor Amplification with Age:

17.3 Age-Specific Monitoring Protocols

Younger Women (45-54):

Middle-Aged Women (55-64):

Older Women (65+):

17.4 Age-Adjusted Dose Titration

Titration Guidelines:

17.5 Timing Hypothesis Application

The "Window of Opportunity":

Angeliq-Specific Considerations:

18. Drug Interactions: Potassium Concerns (Expanded)

18.1 Hyperkalemia Risk Stratification

Risk Tier Classification:

18.2 Comprehensive Drug Interaction Matrix

Potassium-Affecting Drug Interactions:

18.3 Multi-Drug Scenario Management

Common Real-World Combinations:

18.4 Clinical Scenarios and Decision Trees

Scenario 1: Patient on Lisinopril for Hypertension

Patient on Lisinopril → Starting Angeliq?
├── Baseline K+ <4.5 mEq/L
│   └── Proceed with Tier 2 monitoring
│       └── K+ Week 2: <5.0 → Continue, check Week 4
│       └── K+ Week 2: 5.0-5.5 → Continue, check Week 4, dietary review
│       └── K+ Week 2: >5.5 → Hold Angeliq, reassess
├── Baseline K+ 4.5-5.0 mEq/L
│   └── Proceed with Tier 3 monitoring
│       └── K+ Week 1: <5.0 → Continue, check Week 2
│       └── K+ Week 1: >5.0 → Consider alternative HRT
└── Baseline K+ >5.0 mEq/L
    └── Do not start Angeliq; use Activella or transdermal

Scenario 2: Patient Requesting Both Angeliq and Spironolactone

Patient wants Angeliq + Spironolactone (for acne/hirsutism)
├── Contraindicated combination
│   └── DRSP provides anti-MC + anti-androgenic effects
│   └── Spironolactone would be redundant and dangerous
├── Options:
│   └── Angeliq alone (DRSP provides both benefits)
│   └── Alternative E+P + spironolactone (if higher anti-androgen needed)
└── Counsel: DRSP in Angeliq ≈ 12.5 mg spironolactone anti-MC equivalent

18.5 Potassium Monitoring Protocol Details

Tier 2 Protocol (Moderate Risk):

Tier 3 Protocol (High Risk):

18.6 Signs and Symptoms of Hyperkalemia

Patient Education Points:

When to Stop Angeliq Emergently:

19. Bloodwork Impact

19.1 Expected Laboratory Changes

Hormonal Parameters:

19.2 Metabolic Panel Effects

Electrolytes:

Renal Function:

Glucose Metabolism:

19.3 Lipid Profile Effects

Lipid Changes with Angeliq:

Triglyceride Management:

19.4 Liver Function Impact

Hepatic Parameters:

Clotting Factors (Oral Estrogen Effect):

19.5 Thyroid Function Impact

Thyroid Parameters:

In Hypothyroid Patients on Levothyroxine:

19.6 Coagulation Studies

Baseline and Monitoring:

19.7 Complete Bloodwork Protocol

Recommended Testing Schedule:

Additional Testing as Indicated:

20. Protocol Integration

20.1 Integration with Overall HRT Protocol

Position of Angeliq in HRT Algorithm:

Postmenopausal Woman with Intact Uterus Seeking HRT
├── Assess VTE Risk
│   ├── High VTE Risk → Transdermal E+P (Climara Pro, CombiPatch)
│   └── Standard VTE Risk → Continue Assessment
├── Assess Renal Function
│   ├── eGFR <30 → Avoid Angeliq; use Activella or transdermal
│   ├── eGFR 30-60 → Use Angeliq with caution (Tier 3 monitoring)
│   └── eGFR >60 → Continue Assessment
├── Assess Specific Needs
│   ├── Fluid Retention/Bloating → Angeliq (anti-MC benefit)
│   ├── Mild Hypertension → Angeliq (BP-lowering potential)
│   ├── Acne/Hirsutism → Angeliq (anti-androgenic)
│   ├── Standard Needs, Cost-Sensitive → Generic Activella
│   └── Multiple K+-Elevating Drugs → Activella or transdermal
└── Initiate Chosen Product with Appropriate Monitoring

20.2 Combination with Other Therapies

Angeliq + Vaginal Estrogen:

Angeliq + Testosterone:

Angeliq + DHEA:

20.3 Switching Protocols

From Other Oral E+P to Angeliq:

From Angeliq to Other Products:

From Transdermal to Angeliq:

20.4 Integration with Cardiovascular Medications

With Antihypertensives:

Dose Adjustment Considerations:

20.5 Perioperative Protocol

Before Elective Surgery:

Post-Surgical Resumption:

20.6 Monitoring Integration Timeline

Comprehensive Monitoring Schedule:

20.7 Documentation Requirements

Required Documentation Elements:

20.8 Discontinuation Protocol

Planned Discontinuation:

Post-Discontinuation Monitoring:

Document Completion: 2025-12-26 Revision: 2026-01-05 - Added Goal Archetype Integration, Age-Stratified Dosing, Expanded Drug Interactions (Potassium), Bloodwork Impact, and Protocol Integration sections Status: PAPER 43 OF 76 COMPLETE Next Paper: #44 - Toremifene